Investigation finds firms, which are supposed to control spending, have overcharged for cancer drugs and taken other steps raising costs
Firms that manage drug benefits, which promise to keep a lid on high drug costs, instead steer patients away from less expensive medicines and overcharge for cancer therapies, Federal Trade Commission investigators found.
The FTC detailed, in a report released Tuesday, a number of actions that it said large pharmacy-benefit managers use to boost their profits and increase the spending of the health plans and employers that hired them to control costs. The actions can also lead to higher outlays for patients at the pharmacy counter, the agency said.
Comments